On Wednesday, Truist Securities adjusted its outlook on shares of Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company, by reducing its price target from $18.00 to $13.00. The firm has decided to maintain its Hold rating on the stock.
The revision comes amid evaluations of Sage's drug developments, particularly Zurzurvae, which has been acknowledged for its potential in addressing postpartum depression (PPD (NASDAQ:PPD)) and its successful launch in collaboration with Biogen Inc. (NASDAQ:BIIB). Truist Securities has expressed satisfaction with the current trajectory of Zurzurvae's total prescriptions, which are expected to increase as more sales forces are deployed in the fourth quarter of 2024.
Despite the positive developments with Zurzurvae, Truist Securities has signaled caution regarding the company's pipeline updates concerning Alzheimer's disease (AD) and Huntington's disease (HD) for the remainder of 2024. The firm cites a lack of conviction in these areas, suggesting that there may be further downside risks associated with these updates.
The analyst from Truist Securities stated, "We like what we're seeing in Zurzurvae. It shows SAGE is capable of developing drugs for high unmet need such as PPD and launch successfully in partnership with BIIB." They added, "We'd rather wait for pipeline events to be fleshed out before we make an attempt at a differentiated call on SAGE."
The decision to maintain a Hold rating reflects a stance of watchful optimism, with Truist Securities preferring to observe the unfolding events in Sage Therapeutics' pipeline before making further assessments. The reduction of the price target to $13.00 from $18.00 is a strategic response to the anticipated challenges and uncertainties in the company's drug development programs beyond Zurzurvae.
In other recent news, Sage Therapeutics has been the subject of several financial firm adjustments following mixed second quarter results. Piper Sandler cut its price target for the company to $52 while maintaining an Overweight rating. Mizuho Securities and Stifel also adjusted their outlooks, reducing their price targets to $12 and $15 respectively, while maintaining their previous ratings.
Sage Therapeutics reported $7.4 million in collaboration revenue for Q2 2024, attributed to the successful launch of its product, Zurzuvae. Despite sales figures for Zurzuvae falling short of some expectations, the product saw a significant 67% quarter-over-quarter increase in written prescriptions. The company also announced plans for a salesforce expansion in the fourth quarter of 2024 to foster growth in 2025.
Moreover, Sage Therapeutics provided updates on the development of dalzanemdor (SAGE-718) for Huntington's Disease (HD) and Alzheimer's Disease (AD), including an adjustment in the DIMENSION study's primary endpoint.
Despite these developments, the company ended Q2 with a net loss of $102.9 million but reported having $647 million in cash, projecting funding to last until 2026. These are recent developments that investors should be aware of.
InvestingPro Insights
As Sage Therapeutics navigates the competitive landscape of biopharmaceuticals, it's crucial for investors to monitor the company's financial health and market performance. According to InvestingPro, Sage Therapeutics holds a market capitalization of approximately $497 million. Despite impressive revenue growth over the last twelve months, with an increase of over 837%, the company's financial metrics indicate some challenges. Sage's gross profit margin stands at a concerning -213.59%, reflecting costs that far exceed revenues.
InvestingPro Tips for Sage Therapeutics reveal a mixed picture. On the positive side, the company has more cash than debt on its balance sheet, and liquid assets exceed short-term obligations, which may provide some financial flexibility. However, analysts have revised their earnings downwards for the upcoming period, and they do not expect the company to be profitable this year. Additionally, the stock has experienced a significant decline over the past six months, currently trading near its 52-week low.
For investors considering Sage Therapeutics, these insights could be pivotal in making informed decisions. It's worth noting that there are additional InvestingPro Tips available which could further guide investment strategies. As the company continues to develop its pipeline, keeping an eye on these financial and market indicators will be key.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.